• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

What You Need to Know About Axim's IBS & MS Clinical Trials

June 19, 2017

 

AXIM Biotechnologies, Inc. (OTC:AXIM) announced today that the company has secured $4 million in institutional financing to further advance its clinical trials for the treatment of irritable bowel syndrome ("IBS"), pain and spasticity in multiple sclerosis ("MS").

 

In addition to the advancement of AXIM's clinical trials, the funding will also allow the company to continue a bio-equivalency study on creating an alternative to AbbVie's (NYSE:ABBV) FDA-approved Marinol drug using the company’s patented chewing-gum delivery system.

 

Robust Development Pipeline

 

“This financing enables us to continue to build on the progress we have made with our cannabinoid clinical development program for indications where there are currently no effective treatments,” said George Anastassov, MD, the CEO of AXIM.

 

Anastassov continued, “it is encouraging to see that investors recognize the potential of our robust clinical development pipeline. We are now better positioned to execute on cannabinoid research and commercialization.”

 

 

AXIM's Chewing Gum Technologies

 

AXIM's MedChew Rx is a THC/CBD controlled-release chewing gum, which is currently undergoing clinical research to treat pain and spasticity in patients with multiple sclerosis. AXIM aims to capture a portion of the massive MS treatment market, which Grand View Research, Inc. estimates will grow to $24.8 billion USD by 2024.

 

According to the same research, the major companies currently operating in the multiple sclerosis treatment market are Biogen (NASDAQ:BIIB), Teva Pharmaceuticals (NYSE:TEVA), Bayer Healthcare (OTC:BAYRY), Pfizer (NYSE:PFI), Sanofi (NYSE:SNY), Merck (NYSE:MRK), Novartis (NYSE:NVS), and AbbVie. If AXIM's product were to become FDA approved for these indications, it would catapult the company into the ranks of the aforementioned biotech giants. 

 

AXIM's CanChew Plus is the company's "new and improved functional chewing gum" with a higher active pharmaceutical ingredient of CBD, and is currently undergoing Phase II clinical trials for treatment of IBS at the University of Wageningen in The Netherlands. CanChew Plus uses AXIM's patented microencapsulation technology for increased bioavailability and absorption. 

AXIM's MedChew Dronabinol is a prototype chewing gum that the comapny is developing with a U.S.-based controlled-substances API company as a bio-equivalent product to AbbVie's Marinol® for treatment of nausea and loss of appetite in cancer treatment patients. This would offer patients the ability to choose between the existing dronabinol capsules on the market and a controlled release chewing gum. Dronabinol is a laboratory-made equivalent of delta-9-THC, an active ingredient found in cannabis plants. 

 

Conclusion

 

For more information on AXIM Biotechnologies, Inc., be sure to check out the company's marijuana stock profile in our biotech marijuana stock database. For a comprehensive list of all marijuana stocks, be sure to check out our complete marijuana stock database. 

 

Be sure to subscribe to one or more of our free newsletters so you never miss an important marijuana update. Also, don't forget to connect with The Daily Marijuana Observer on Facebook, Twitter, and Instagram if you haven't already. 

 

D/M/O

 

 

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.